Clinical TrialsForte Biosciences has dosed the first patients in their Phase 2 trial for their lead asset FB102 in celiac disease, with data expected to be positive given strong results from the previous Phase 1b trial.
Financial PerformanceThe company recently closed a $70 million net public offering, bringing their cash reserves to $106 million, which supports ongoing and future trials.
Research And DevelopmentThe upcoming readout is expected to be positive given rational CD122-targeting MoA and best-in-class potency.